Premature Ovarian Insufficiency: Aetiology and Long-Term Consequences

Naina Kumar, MD, Isha Manesh, MD Student

Student Department of Obstetrics and Gynecology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana-133207, Ambala, Haryana, IndiaIndia

DOI: https://doi.org/10.17140/whoj-3-121 · Published 2017-03-07 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2017 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Keywords: Amenorrhoea; Menopause; Ovary; Ovulation; Stem cells; Amenorrhoea; Menopause; Ovary; Ovulation; Stem cells

Introduction

Premature ovarian insufficiency (POI) also known as Premature ovarian failure or Hypergonadotropic ovarian failure or Menopausa precoce1 is defined as a primary ovarian defect, characterized by an absent menarche (primary amenorrhea) or premature loss of ovarian follicles before 40 years of age (secondary amenorrhea). 2,3 Characteristic features include cessation of ovulation or amenorrhoea for 4 months or more, hypoestrogenism (estradiol levels <50 pg/ ml)4 and high serum gonadotropin levels,5,6 especially two serum follicle-stimulating hormone (FSH) levels (>4 weeks apart) in menopausal range7,8 (>40 IU/l).4 POI was previously known as premature menopause, but this term is a misnomer, as all women with POI do not always stop menstruating, neither do their ovaries shut down completely.8 In most women aged >40 years, there is a physiological decline in ovarian function with aging which is called as perimenopause/menopausal transition.9 Ovarian ageing resulting in ovarian failure and menopause is a continuous process5,10 and menopause is usually attained at 51 years (range 40-60 years).11-13 The World Health Organization (WHO) defines menopause as permanent cessation of menstruation due to ovarian follicular activity loss.13 Page 46 POI differs from menopause as, in POI unpredictable and varying degrees of ovarian functions are still present in 50% of women, and about 5-10% can even conceive and deliver child after diagnosis and treatment.7,8,14 It is a hypergonadotropic and hypogonadism state resulting from depletion/dysfunction of ovarian follicles due to either low initial numbers or acceler ated loss.15 Premature loss of ovarian function leads to significant long-term psychosocial sequelae and major health complications.16 It also results in age-specific increase in mortality rate.17,18 Based on the age of onset, POI can present itself as primary amenorrhea, without onset of menarche, or secondary amenorrhea after puberty. 3 It is a continuum of disorders with four clinical states which are not permanent. Patients usually budge from one state to another in an unknown manner.19 These states are as follows: 1. Occult POI presents as unexplained infertility with normal baseline serum FSH levels.

2. Biochemical POI presents as unexplained infertility with elevated basal serum FSH levels.

3. Overt POI previously known as premature ovarian failure is characterized by elevated serum FSH levels with associated menstrual disorders like oligomenorrhea, polymenorrhea, and metrorrhagia.

4. POI is an extreme state of total primordial follicle depletion; an irreversible state characterized by anovulation, amenor rhea, infertility, and elevated gonadotropin levels.

Incidence

POI is relatively common, with an estimated occurrence of 1 in 100 by 40 years; 1 in 1000 by 30 years 11,12 and 1 in 10,000 by 20 years of age.1,20,21 It affects around 1-3% of women in the reproductive age below 40 years and around 0.1% in women below 30 years of age. 2,10,18,22,23 Women with POI, around 10-28% experience primary amenorrhea and 4-18% secondary amenor rhea.10,18 Incidence of spontaneous onset POI has increased due to increasing success rates of cancer treatment in girls and young women.20,24,25 On the other hand, familial POI accounts for 15- 30% of all cases.1,12,26 Pathogenesis Process of human folliculogenesis being highly complex and organised, is characterised by progressive maturation of small primordial follicles to larger ovulatory follicles. This whole process occurs continuously, and can stretch over a period of a year. 27 Reproductive life span of human females start with a fixed number of primordial follicles,28 of which only 400-500 develop and ovulate before physiological menopause (Figure 1).29 On the other hand, exact mechanism for development of POI is not known. It can be due to: a) Preliminary decrease in primordial follicle pool; b) Accelerated atresia of follicles; c) Defective maturation/recruitment of primordial follicles (Figure 1).29 Furthermore, accelerated follicular atresia can be because of changed apoptosis rate, defective follicle maturation blocking and abnormalities in primordial follicle activation that causes decreased number of available functional follicles/accelerated Figure 1: (A) Normal Physiology of Foloocular Development. (B) Mechanism of Origin of Premature Ovarian Insufficiency.29

Page 47 atresia.30,31 Hence, factors that initiate such mechanisms are highly heterogeneous and can be a result of, genetic mutations, chromosomal, infectious, autoimmune, metabolic and iatrogenic factors.18,29 AETIOLOGICAL FACTORS Genetic Factors Genetic factors are most commonly responsible for POI accounting for 7% of all cases. 3,5,32 X chromosome is most commonly affected, but autosomal involvement is also common.18,33 Aneuploidies and rearrangements are most commonly reported with POI34 (Figure 2).29 X CHROMOSOME Monosomy (45 X) Terminal deletions of long arm of X chromosome result in primary amenorrhea and absence of breast development in all cases.12,35 Total or near total absence of single X chromosome,18 known as Turner’s syndrome affects around 1 in 2500 live female births and is usually associated with ovarian dysgenesis leading to primary amenorrhea. However, 3-5% of such females with Turner mosaic karyotype can menstruate and even develop secondary sexual characteristics. Turner syndrome is associated with 4-5% POI cases.12,36,37 Trisomy Trisomy affects 1 in 1000 women. 12,18 Trisomy X females usually have normal ovarian function, but in some, it may manifest as early menopause, secondary amenorrhea, oligomenorrhea.10,38 Around 10% of females have mosaicism with 46, XX/47, XXX or 45, X/47, XXX karyotypes. Manifestations depend on time at which causing events occurred. 10 Ovarian failure in females with 47, XXX (mosaic/non-mosiac) can be due to meiotic inadequacy of three X chromosomes, which is still unproven. 10,34 However, cytogenetic studies in women with POI have shown that trisomy X (mosaic/non-mosaic patterns) have very low incidence of POI.10,39,40 Fragile X Syndrome Fragile X syndrome is an X-linked dominant genetic condition characterised by expansion of trinucleotide repeat 41 with prevalence of 1/6000 in females and 1/4000 in males. 42,43 It is a common cause of hereditary mental retardation and developmental delay.43,44 Fragile X mental retardation 1 (FMR1) gene is located on X chromosome at Xq27.3. There is expansion of CGG trinucleotide repeats in 5′ untranslated region of first exon of FMR1 gene. Affected females show >200 CGG repeats, as compared to normal (5-54 CGG repeats). This expansion of >200 repeats causes methylation-coupled silencing of FMR1 gene resulting in loss of FMR-protein which is important for brain development in prenatal and postnatal period.41,43,45 Recently, it was reported that higher number of CGG Figure 2: Genes involved in Pathogenesis of Premature Ovarian Insufficiency.29

Page 48 repeats (>30-40) can be used to detect premature ovarian aging and POI in infertile women.43,46 An estimated 16-26% of female with FMR1 premutation carriers develop POI, 43,47,48 whereas only 2% of normal women develop isolated POI.49 They are also known to develop tremor-ataxia syndrome, 50 mild neuro-cognitive dysfunction.51 It was also reported that paternally inherited Fragile X premutations were more likely to be associated with POI as compared to maternally inherited permutations.52 Bone Morphogenetic Protein 15 Gene (BMP15) Bone morphogenetic proteins (BMPs) are proteins belonging to transforming growth factor-β (TGF-β) superfamily, which play an important role in oocyte-specific growth/differentia tion factors that help in follicle maturation and granulosa cell growth.18,29,53,54 BMP15 gene is located on the short arm of Chromosome X (Xp11.2) within ‘POI critical region’. 18,29,55 BMP15 mutations are associated with 1.5-12% of POI cases. 1,56-60 This defect is an unusual example of X-linked disease in which affected females inherit mutation from their unaffected father.1,56 Autosomal Genes Genetic studies have shown various isolated gene defects associated with POI, which are: a) Estrogen receptor (ER-α and ER-β) mutations,12,35 b) FSH receptor mutations (FSHr),61,62 associated with <1% POI cases.1,32, 60,63 c) LH receptor mutations (LHr)64 associated with <1% POI cases.1,32,60,63 d) FOXL2 mutations: Occurs with either blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) type 1 (without POI) or BPES type 2 (with POI), known as POI-3.1,65,66 e) Steroidogenic factor 1 (NR5A1) mutation.12,35 f) CYP19A1 mutation.12,35,67,68 g) Inhibin A gene mutation associated with 5% of POI cases.60,69 h) NOBOX gene: Newborn ovary homeobox gene (NOBOX) plays role in initial phases of follicular maturation70 and is rarely associated with POI.71,72 Despite several genes shown to be associated with POI, the exact mechanism still remains uncertain.54,56,65,73 Autoimmune Factors Autoimmunity is characterized by auto-reactive lymphocytosis, organ and non-organ-specific autoantibodies.74,75 It accounts for 4-30% of POI cases1,8,76-82 and is characterised by presence of antiovarian antibodies (AOAs), lymphocytic oophoritis on histopathological examination, in association with other autoimmune conditions.82-86 Exact mechanism of autoimmune POI remains obscure and may be due to genetic and or environmental factors that are responsible for initiating immune response.43,75,83,87,88 Important factors involved are: Major histocompatibility complex antigen (HLA), cytokines, cell-mediated immunity, antibodymediated immunity, etc.43,75,83,87,88 There are three main types of autoimmune POI: Adrenal autoimmune POI, non-adrenal autoimmune POI and isolated idiopathic POI.43,88,89 Autoimmune causes in pathogenesis of POI is characterised by presence of autoantibodies directed towards the ovarian tissue.84,90,91 These AOAs can be detected in the serum of affected females before clinical onset of POI. 92 These antibodies bind to various steroid hormone-producing cells 8,14, 82,93,94 like adrenal cortex cells, theca cells of ovary, placental syncytiotrophoblast cells, and are known as steroid cell antibodies (StCAs).82 They also bind to gonadotropins and their receptors,95-97 zona pellucid,98 oocyte,99 corpus luteum,84,100 and can act as markers of ovarian autoimmunity.82 Furthermore, it was observed that POI has strong association with autoimmune Addison’s disease. Around 60-87% cases of POI have Addison’s disease. 14,82,90,93,101 There are two types of autoimmune polyendocrine syndromes (APS) 5,74,75 strongly associated with POI. Type 1 APS [autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED)] characterized by combination of hypoparathyroidism, adrenal failure, and chronic mucocutaneous candidiasis. It is usually seen in children and is associated with POI in 60% cases presenting as primary amenorrhoea. Type II APS is characterised by autoimmune Addison’s disease with adrenal insufficiency and other autoimmune illnesses without hypoparathyroidism.5,74 It usually occurs between the third to fourth decades of life and is associated with POI in 25-40% cases.14,82,90,93,101 Other autoimmune conditions commonly associated with POI are: hypothyroidism,102-104 autoimmune adrenal insufficiency,105 hypoparathyroidism,79 type 1 diabetes mellitus, hypophysitis, autoimmune haemolytic anaemia, celiac disease, inflammatory bowel diseases, glomerulonephritis,5 Sjogren’s syndrome 106 and myasthenia gravis.89 Iatrogenic Iatrogenic causes for POI are increasing due to rise in incidence of various gynaecological cancers and their successful treat ment.107,108 Oocyte is highly radiosensitive and responds to even 2 Gray dose of radiotherapy.43,109 Hence, an ovarian radiotherapy dose of ≥6 Gray results in ovarian insufficiency in almost all females over 40 years of age. 110 Effect of radiotherapy on ovaries is dependent on dose, age, and radiation therapy field. 43,111, 112 Chemotherapy also causes ovarian insufficiency but exact mechanisms are not clear; however, it is well known that chemotherapeutic agents affect granulosa cell functions and oocytes, ultimately causing ovarian insufficiency. 43,113 Major predictive factors for development of ovarian insufficiency after chemotherapy are; age, class, dose of chemotherapeutic agent, concurrent use of radiotherapy, etc.43,108,114 It has been reported that use of alkylating agents (N-mustard, L-phenylalanine mustard, Chlorambucil, Busulfan, and Cyclophosphamide) are strongly associated with POI (40%).12 Page 49 Furthermore, it has been reported that ovarian drilling for polycystic ovarian syndrome and chocolate cysts removal for endometriosis are associated with early menopause. 12,115 Recent literature reports that uterine artery embolization also leads to POI by affecting ovarian vascular supply.43,116 Hence, it was observed that almost any pelvic surgery, be it ovarian cyst removal or hysterectomy–can affect ovaries and lead to POI, by affect ing vascular supply or by causing inflammation in pelvic area.117 Studies have shown that in some cases of POI, ovarian function may return spontaneously many years after chemotherapy and/ or radiotherapy118,119 and many successful pregnancies can also occur in such women.43 Infectious and Toxic agents Till date there are no direct evidences available that suggest correlation between infections and POI, but studies report that Mumps oophoritis may be related to development of POI. True reason of post-oophritis ovarian failure is unknown.5,43,120 In vast majority of affected women, return of ovarian function occurs following recovery.18,43 Another infectious agent and its treat ment that can be linked with POI is HIV infection.5,121 It has been reported that around 3.5% of females with POI have a history of infections like varicella, tuberculosis shigellosis, malaria and cytomegalovirus.7,43,80 Amongst the various toxins that are strongly associated with POI, smoking is one major toxin. It was found that there is an inverse relationship between number of cigarettes smoked per day and age at menopause.43,122 Smoking causes alteration of ovarian function, and leads to early menopause in female who smoke as compared to non-smokers.43,123 Other toxins that commonly affect ovarian functions and can lead to POI are: Polycyclic aromatic hydrocarbons (PaHs), toxic chemicals in tobacco, heavy metals, insecticides, plastics and industrial chemicals, but exact underlying mecha nism is unclear.5,18 Clinical Course Women with POI are typically observed with secondary amenorrhea/menopause, many a times preceded by irregular menstrual cycle at age <40 years.20,78 In few women with primary amenorrhea, the cause can be an underlying chromosomal abnormali ty.20 Other characteristic symptoms include hot flushes and night sweats20,124; these are mainly due to estrogen deficiency. 118,125 Vaginal symptoms include dyspareunia and dryness, which can be distressing for women.125,126 In addition to these, women also suffer from sleep disturbances, mood swings, lack of concentration, depression, loss of libido, dry eyes, 127 altered urinary frequency and lack of energy.117,125 These symptoms are usually transient and are mainly due to changes in ovarian functions (estrogen withdrawal rather than deficiency) that result from spontaneous onset of POI.125,128 Furthermore, it was observed that in women with surgically induced POI, symptoms are more severe and persistent.125 Diagnosis and Assessment Diagnosis of POI can be easily made on clinical presentation, in woman <40 years of age with amenorrhea or oligomenorrhea of 4-6 months with two measurements of elevated FSH levels. Final diagnosis can be made on certain investigations which include125: Gonadotropin Levels: Both FSH and LH are elevated in women with POI (hypergonadotropic amenorrhea). Elevated FSH levels are more significant than LH. High FSH levels are considered as gold standard for diagnosis of POI and values >25 U/L on two occasions, more than 4 weeks apart is indicative of ovarian insufficiency.125 Low Estrogen levels: Estradiol (E2) levels <50 pg/ml is typically observed in women with POI. 78 Low estradiol levels in combination with high FSH and LH levels are diagnostic of POI. Antimullerian Hormone (AMH): AMH is homodimeric glycoprotein consisting of two subunits, 129,130 and is produced by granulosa cells of growing follicles.131 It regulates early follicular recruitment from primordial pool 132 and is a good reflector of ovarian reserve. 133-135 AMH levels are usually very low or undetectable in women with POI. 136 Hence, AMH testing may become important diagnostic tool for assessment of ovarian reserve before and after chemotherapy in young women with pelvic cancers, before and after ovarian surgery, and for females at high risk of POI.137,138 Inhibin B: It is produced by granulosa cells of growing follicles,139 but its levels show significant variability between menstrual cycles. Hence, it is usually not recommended for diagnosis of POI.138 Once diagnosis of POI is made, other investigations include: • Karyotyping and fragile X mental retardation 1 (FMR-1) premutation for genetic cause8 • Screening for autoimmune diseases like anti-adrenal, anti- 21-hydroxylase,8 anti-thyroid peroxidase, anti-thyroglobulin antibodies125 and AOA are recommended.

Future Fertility

Around 5-10% of women with POI conceive spontaneously due to fluctuations in ovarian functions.12,125,140 Till date no clear guidelines or drugs are available that can cause follicular development or increase fertility in women with POI.125 Various studies have tried to examine the role of ovulation inducing drugs, gonadotrophins, glucocorticoids, GnRH agonists and antagonists,141 but no clear advantage has been observed.12 Page 50 However, fertility preservation techniques can be considered for women at risk of developing POI due to disease or its management. Considerably high rates of natural pregnancies were reported in such women who underwent fertility preser vation pre-treatment.125,142 Another way of improving fertility in women with POI due to sterilizing surgeries is replacement of cryopreserved ovarian tissue, but this has been studied in very few cases.125,143 Recent advances have shown that oocyte donation is another option for women with POI desiring pregnancy.125 Such a successful pregnancy was first reported in 1984 144 and since then it has become a ‘routine’ treatment.

Long-term Consequences of POI /Premature Menopause Bone Health

Estrogen is known for its beneficial effects on bone growth. It is responsible for increased bone remodelling and hence its deficiency is associated with bone loss, decreased mineral density and fracture risk, as seen after natural menopause.145,146 Net bone loss after menopause is usually 2-3% per year. 147 Effect of estrogen deficiency on bone in women with POI is one of most clearly recognized adverse effects of POI. It usually remains asymptomatic for many years, until fragility fracture happens. Furthermore, depending on degree and duration of estrogen deficiency, women with POI develop reduced bone mineral density earlier as compared to normal females.148,149 An estimated 8-14% of women with POI suffer from osteoporosis 148 as compared to normal females.150 Cardiovascular Estrogen has cardio-protective effects and its early loss leads to increased risk of cardio-vascular mortality. 138,151 Hence, women with POI are associated with high risk of cardio-vascular mortality.78,125,138,151 Various researches have proven that women with spontaneous POI suffer early onset coronary heart disease152 and are at increased risk of dying from coronary vascular diseases (CVDs).125,153,154 Furthermore it has been observed that women with pre-menopausal estrogen deficiency develop signs of endothelial dysfunction155 and premature atherosclerosis very ear ly.125,156 It is well proven that estrogen plays an important role in ventricular contractile function, 125,157 decreases insulin resistance125,158 and protects against lipid peroxidation, thereby playing an important role in cardio-protection.

Cognitive and Neurological Health

Few studies have observed the effects of POI on neurological health of women.125 POI, especially the one resulting from bilateral oophorectomy before onset of natural menopause, increases risk of cognitive impairment/dementia. This risk is found to be inversely proportional to the age at which oophorectomy is performed.12,159,160 Such women are also prone to develop Parkinsonism later in their life. 12,159,160 Hence, it is very important to explain all possible detrimental effects on neurological health before planning for hysterectomy and/or oophorectomy in women <50 years, especially for prophylactic reasons.125 Sexual and Genito-urinary Functions In most women with POI, sexual problems are due to physiological stress, or secondary reaction to emotional stress of diagnosis and infertility resulting from the disease.161 Furthermore, fertility treatment has unpredictable outcomes which leads to emotional stress and affect sexual functions in the long run.125,162 Hence, to hold POI as the sole cause for sexual dysfunction may be incorrect, also there are no direct evidences to evaluate effects of POI on sexuality.163 Most common symptoms are those related to estrogen deficiency, which include vasomotor symptoms, sleep distur bances, depression, fatigue, loss of libido, vaginal dryness and dyspareunia.125,164 Endocrine Diseases Women with POI are prone to develop endocrine disorders later in their life. Around 20% with idiopathic POI develop hypothyroidism and most commonly Hashimoto thyroiditis.23 They also carry high risk of developing adrenal insufficiency.138 Future Perspectives Most recent studies have shown the role of stem cells in the treatment of POI and have reported that oocytes can be gener ated from embryonic stem cells (ESCs).165,166 These ESCs are induced into primordial germ cells which are then aggregated with somatic cells of female embryonic gonads for fertilisation.166,167 Other pluripotent cells that have been studied for use include, mesenchymal stem cells (MSCs) used for repairing damaged ovaries induced by chemotherapy. 168 Umbilical cord mesenchymal stem cells (UCMSCs) can also be used with advantage of little or no immune rejection.169 Adipose-derived stem cells (ADSCs) are another type of MSC that can be differentiated into multiple cell types.170 Bone marrow transplantation has also been studied for use in women with poor ovarian function after long-term chemotherapy.166,171 Hence, it is possible that with the latest research and advancement, ovarian aging may become reversible in the future, especially in women with POI.172

Acknowledgement

I acknowledge and thank Dr. Namit Kant Singh for his advice and expertise.

Conflicts Of Interest

There are no conflicts of interest.

Page 51

References

1. Beck-PeccozPPersaniL. Premature ovarian failure. Orphanet J Rare Dis. 2006; 1: 9. doi: 10.1186/1750-1172-1-910.1186/1750-1172-1-9 https://doi.org/10.1186/1750-1172-1-9
2. SantoroN. Mechanisms of premature ovarian failure. Ann Endocrinol (Paris). 2003; 64(2): 87-92. doi: AE-04-2003-64-2- 0003-4266-101019-ART06
3. TimmreckLSReindollarRH. Contemporary issues in primary amenorrhea. Obstet Gynecol Clin North Am. 2003; 30(2): 287-302. doi: 10.1016/S0889-8545(03)00027-510.1016/s0889-8545(03)00027-5 https://doi.org/10.1016/s0889-8545(03)00027-5
4. JinMYuYHuangH. An update on primary ovarian insufficiency. Sci China Life Sci. 2012; 55(8): 677-686. doi: 10.1007/ s11427-012-4355-2
5. Hernández-AngelesCCastelo-BrancoC. Early menopause: A hazard to a woman’s health. Indian J Med Res. 2016; 143(4): 420-427. doi: 10.4103/0971-5916.18428310.4103/0971-5916.184283 https://doi.org/10.4103/0971-5916.184283
6. KumarMPathakDVenkateshSKriplaniAAmminiACDadaR. Chromosomal abnormalities & oxidative stress in women with premature ovarian failure (POF). Indian J Med Res. 2012; 135(1): 92-97. doi: 10.4103/0971-5916.9343010.4103/0971-5916.93430 https://doi.org/10.4103/0971-5916.93430
7. RebarRWConnollyHV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril. 1990; 53(5): 804-810
8. NelsonLM. Primary ovarian insufficiency. N Engl J Med. 2009; 360(6): 606-614. doi: 10.1056/NEJMcp080869710.1056/nejmcp0808697 https://doi.org/10.1056/nejmcp0808697
9. HewlettMMahalingaiahS. Update on primary ovarian insufficiency. Curr Opin Endocrinol Diabetes Obes. 2015; 22(6): 483-489. doi: 10.1097/MED.000000000000020610.1097/med.0000000000000206 https://doi.org/10.1097/med.0000000000000206
10. PouresmaeiliFFazeliZ. Premature ovarian failure: A critical condition in the reproductive potential with various genetic causes. Int J Fertil Steril. 2014; 8(1): 1-12. Web site. http://ijfs. ir/journal/article/fulltext/3756.html. Accessed January 27, 2017
11. SükürYEKıvançlıIBOzmenB. Ovarian aging and premature ovarian failure. J Turk Ger Gynecol Assoc. 2014; 15(3): 190-196. doi: 10.5152/jtgga.2014.002210.5152/jtgga.2014.0022 https://doi.org/10.5152/jtgga.2014.0022
12. FentonAJ. Premature ovarian insufficiency: Pathogenesis and management. J Midlife Health. 2015; 6(4): 147-153. doi: 10.4103/0976-7800.17229210.4103/0976-7800.172292 https://doi.org/10.4103/0976-7800.172292
13. Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1996; 866: 1-107
14. BakalovVKAnastiJNCalisKA. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril. 2005; 84(4): 958-965
15. LittleDTWardHR. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: A case series seen in general practice. J Investig Med High Impact Case Rep. 2014; 2(4): 2324709614556129. doi: 10.1177/232470961455612910.1177/2324709614556129 https://doi.org/10.1177/2324709614556129
16. TaylorAE. Systemic adversities of ovarian failure. J Soc Gynecol Investig. 2001; 8(1): S7-S9. Web site. http://journals.sagepub.com/doi/abs/10.1177/1071557601008001s03. Accessed January 27, 201710.1177/1071557601008001s03.accessed https://doi.org/10.1177/1071557601008001s03.accessed
17. SnowdonDAKaneRLBeesonWL. Is early natural menopause a biologic marker of health and aging? Am J Public Health. 1989; 79(6): 709-714. doi: 10.2105/AJPH.79.6.70910.2105/ajph.79.6.709 https://doi.org/10.2105/ajph.79.6.709
18. GoswamiDConwayGS. Premature ovarian failure. Hum Reprod Update. 2005; 11(4): 391-410. doi: 10.1093/humupd/ dmi01210.1093/humupd/dmi012 https://doi.org/10.1093/humupd/dmi012
19. MaitiGD. Premature ovarian failure: A chronic debilitating condition of womanhood. In: Talwar P, ed. Manual of Cytoge netics in Reproductive Biology. London, UK: JP Medical Ltd; 2014: 119-120
20. ZangmoRSinghNSharmaJB. Diminished ovarian reserve and premature ovarian failure: A review. IVF Lite. 2016; 3(2): 46-51. doi: 10.4103/2348-2907.19228410.4103/2348-2907.192284 https://doi.org/10.4103/2348-2907.192284
21. LuborskyJLMeyerPSowersMFGoldEBSantoroN. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003; 18(1): 199-206. doi: 10.1093/humrep/deg00510.1093/humrep/deg005 https://doi.org/10.1093/humrep/deg005
22. SkillernARajkovicA. Recent developments in identify ing genetic determinants of premature ovarian failure. Sex Dev. 2008; 2(4-5): 228-243. doi: 10.1159/00015203910.1159/000152039 https://doi.org/10.1159/000152039
23. NelsonLMCovingtonSNRebarRW. An update: Spontaneous premature ovarian failure is not an early menopause. Fertil Steril. 2005; 83(5): 1327-1332
24. SklarCAMertensACMitbyP. Premature menopause in survivors of childhood cancer: A report from the childhood cancer survivor study. J Natl Cancer Inst. 2006; 98(13): 890- 896. doi: 10.1093/jnci/djj24310.1093/jnci/djj243 https://doi.org/10.1093/jnci/djj243
25. PanayNFentonA. Premature ovarian failure: A growing concern. Climacteric. 2008; 11(1): 1-3. doi: 10.1080/1369 713070187863510.1080/1369 https://doi.org/10.1080/1369
26. MurabitoJMYangQFoxCWilsonPWCupplesLA. Heritability of age at natural menopause in the framingham heart Page 52 study. J Clin Endocrinol Metab. 2005; 90(6): 3427-3430. doi: 10.1210/jc.2005-018110.1210/jc.2005-0181 https://doi.org/10.1210/jc.2005-0181
27. PictonHMHarrisSEMuruviWChambersEL. The in vitro growth and maturation of follicles. Reproduction. 2008; 136(6): 703-715. doi: 10.1530/REP-08-029010.1530/rep-08-0290 https://doi.org/10.1530/rep-08-0290
28. ShellingAN. Premature ovarian failure. Reproduction. 2010; 140(5): 633-641. doi: 10.1530/REP-09-056710.1530/rep-09-0567 https://doi.org/10.1530/rep-09-0567
29. PersaniLRossettiRCacciatoreC. Genes involved in human premature ovarian failure. J Mol Endocrinol. 2010; 45(5): 257-279. doi: 10.1677/JME-10-007010.1677/jme-10-0070 https://doi.org/10.1677/jme-10-0070
30. MoritaYTillyJL. Oocyte apoptosis: Like sand through an hourglass. Dev Biol. 1999; 213(1): 1-17. doi: 10.1006/ dbio.1999.9344
31. SullivanSDCastrillonDH. Insights into primary ovarian insufficiency through genetically engineered mouse models. Semin Reprod Med. 2011; 29(4): 283-298. doi: 10.1055/s-0031- 128091410.1055/s-0031-1280914 https://doi.org/10.1055/s-0031-1280914
32. FortuñoCLabartaE. Genetics of primary ovarian insufficiency: A review. J Assist Reprod Genet. 2014; 31(12): 1573- 1585. doi: 10.1007/s10815-014-0342-910.1007/s10815-014-0342-9 https://doi.org/10.1007/s10815-014-0342-9
33. ChapmanCCreeLShellingAN. The genetics of premature ovarian failure: Current perspectives. Int J Womens Health. 2015; 7: 799-810. doi: 10.2147/IJWH.S6402410.2147/ijwh.s64024 https://doi.org/10.2147/ijwh.s64024
34. JiaoXQinCLiJ. Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum Reprod. 2012; 27(7): 2201-2207. doi: 10.1093/humrep/des10410.1093/humrep/des104 https://doi.org/10.1093/humrep/des104
35. SimpsonJL. Genetic and phenotypic heterogeneity in ovar ian failure: Overview of selected candidate genes. Ann N Y Acad Sci. 2008; 1135: 146-154. doi: 10.1196/annals.1429.01910.1196/annals.1429.019 https://doi.org/10.1196/annals.1429.019
36. LuisiSOrlandiniCReginiCPizzoAVellucciFPetragliaF. Premature ovarian insufficiency: From pathogenesis to clini cal management. J Endocrinol Invest. 2015; 38(6): 597-603. doi: 10.1007/s40618-014-0231-110.1007/s40618-014-0231-1 https://doi.org/10.1007/s40618-014-0231-1
37. CoxLLiuJH. Primary ovarian insufficiency: An update. Int J Womens Health. 2014; 6: 235-243. doi: 10.2147/IJWH.S3763610.2147/ijwh.s37636 https://doi.org/10.2147/ijwh.s37636
38. HollandCM. 47, XXX in an adolescent with premature ovarian failure and autoimmune disease. J Pediatr Adolesc Gynecol. 2001; 14(2): 77-80. doi: 10.1016/S1083-3188(01)00075-410.1016/s1083-3188(01)00075-4 https://doi.org/10.1016/s1083-3188(01)00075-4
39. Cordts EB, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP. Genetic aspects of premature ovarian failure: A literature review. Arch Gynecol Obstet. 2011; 283(3): 635-643. doi: 10.1007/s00404-010-1815-4 https://doi.org/10.1007/s00404-010-1815-4
40. TartagliaNRHowellSSutherlandAWilsonRWilsonL. A review of trisomy X (47,XXX). Orphanet J Rare Dis. 2010; 5: 8. doi: 10.1186/1750-1172-5-810.1186/1750-1172-5-8 https://doi.org/10.1186/1750-1172-5-8
41. NolinSLBrownWTGlicksmanA. Expansion of the fragile X CGG repeat in females with premutation or inter mediate alleles. Am J Hum Genet. 2003; 72(2): 454-464. doi: 10.1086/36771310.1086/367713 https://doi.org/10.1086/367713
42. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG committee opinion. No. 338: Screening for fragile X syndrome. Obstet Gynecol. 2006; 107(6): 1483- 1485
43. Ebrahimi M, Akbari Asbagh F. Pathogenesis and causes of premature ovarian failure: an update. Int J Fertil Steril. 2011; 5(2): 54-65. Web site. http://ijfs.ir/journal/article/fulltext/2905. html. Accessed January 27, 2017
44. HagermanRJHagermanPJ. The fragile X premutation: Into the phenotypic fold. Curr Opin Genet Dev. 2002; 12(3): 278- 283. doi: 10.1016/S0959-437X(02)00299-X10.1016/s0959-437x(02)00299-x https://doi.org/10.1016/s0959-437x(02)00299-x
45. BearMFHuberKMWarrenST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27(7): 370-377. doi: 10.1016/j.tins.2004.04.00910.1016/j.tins.2004.04.009 https://doi.org/10.1016/j.tins.2004.04.009
46. FiçiciogluCYildirimGAttarRKumbakBYesildaglarN. The significance of the number of CGG repeats and autoantibodies in premature ovarian failure. Reprod Biomed Online. 2010; 20(6): 776-782. doi: 10.1016/j.rbmo.2010.02.01110.1016/j.rbmo.2010.02.011 https://doi.org/10.1016/j.rbmo.2010.02.011
47. SullivanAKMarcusMEpsteinMP. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005; 20(2): 402-412. doi: 10.1093/humrep/deh63510.1093/humrep/deh635 https://doi.org/10.1093/humrep/deh635
48. WittenbergerMDHagermanRJShermanSL. The FMR1 premutation and reproduction. Fertil Steril. 2007; 87(3): 456-65. doi: 10.1016/j.fertnstert.2006.09.00410.1016/j.fertnstert.2006.09.004 https://doi.org/10.1016/j.fertnstert.2006.09.004
49. ShermanSL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000; 97(3): 189-194. doi: 10.1002/1096-8628(200023)97:3<189::AID-AJMG1036> 3.0.CO;2-J10.1002/1096-8628(200023)97:3 https://doi.org/10.1002/1096-8628(200023)97:3
50. HagermanRJLeavittBRFarzinF. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet. 2004; 74(5): 1051-1056. doi: 10.1086/42070010.1086/420700 https://doi.org/10.1086/420700
51. Van EschH. The fragile X permutation: New insights andclinical consequences. Eur J Med Genet. 2006; 49(1): 1-8. doi: 10.1016/j.ejmg.2005.11.00110.1016/j.ejmg.2005.11.001 https://doi.org/10.1016/j.ejmg.2005.11.001
52. HundscheidRDSistermansEAThomasCM. Imprinting effect in premature ovarian failure confined to paternally in-Page 53 herited fragile X premutations. Am J Hum Genet. 2000; 66(2): 413-418. doi: 10.1086/30277410.1086/302774 https://doi.org/10.1086/302774
53. McNattyKPMooreLGHudsonNL. The oocyte and its role in regulating ovulation rate: A new paradigm in reproductive biology. Reproduction. 2004; 128(4): 379-386. Web site. http://www.reproduction-online.org/content/128/4/379.short. Accessed January 27, 2017
54. ShimasakiSMooreRKOtsukaFEricksonGF. The bone morphogenetic protein system in mammalian reproduction. Endocr Rev. 2004; 25(1): 72-101. doi: 10.1210/er.2003-000710.1210/er.2003-0007 https://doi.org/10.1210/er.2003-0007
55. PersaniLRossettiRCacciatoreCBonomiM. Primary Ovarian Insufficiency: X chromosome defects and autoim munity. J Autoimmun. 2009; 33(1): 35-41. doi: 10.1016/j. jaut.2009.03.00410.1016/j.jaut.2009.03.004 https://doi.org/10.1016/j.jaut.2009.03.004
56. Di PasqualeEBeck-PeccozPPersaniL. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet. 2004; 75(1): 106-111. doi: 10.1086/42210310.1086/422103 https://doi.org/10.1086/422103
57. LaissuePChristin-MaitreSTouraineP. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol. 2006; 154(5): 739-744. doi: 10.1530/eje.1.0213510.1530/eje.1.02135 https://doi.org/10.1530/eje.1.02135
58. RossettiRDi PasqualeEMarozziA. BMP15 muta tions associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat. 2009; 30(5): 804-810. doi: 10.1002/humu.2096110.1002/humu.20961 https://doi.org/10.1002/humu.20961
59. WangBWenQNiF. Analyses of growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) mutation in chinese women with premature ovar ian failure. Clin Endocrinol (Oxf). 2010; 72(1): 135-136. doi: 10.1111/j.1365-2265.2009.03613.x10.1111/j.1365-2265.2009.03613.x https://doi.org/10.1111/j.1365-2265.2009.03613.x
60. OhkuboMYabuTYamashitaMShimizuA. Molecular cloning of two gonadotropin receptors in mummichog Fundulus heteroclitus and their gene expression during follicular development and maturation. Gen Comp Endocrinol. 2013; 184: 75-86. doi: 10.1016/j.ygcen.2012.12.01910.1016/j.ygcen.2012.12.019 https://doi.org/10.1016/j.ygcen.2012.12.019
61. WeiSChenSGongZ. Alarelin active immunization influences expression levels of GnRHR, FSHR and LHR proteins in the ovary and enhances follicular development in ewes. Anim Sci J. 2013; 84(6): 466-475. doi: 10.1111/asj.1203010.1111/asj.12030 https://doi.org/10.1111/asj.12030
62. BeauITourainePMeduriG. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. J Clin Invest. 1998; 102(7): 1352-1359. doi: 10.1172/JCI379510.1172/jci3795 https://doi.org/10.1172/jci3795
63. TourainePBeauIGougeonA. New natural inactivating mutations of the follicle-stimulating hormone receptor: Correlations between receptor function and phenotype. Mol Endocrinol. 1999; 13(11): 1844-1854. doi: 10.1210/mend.13.11.037010.1210/mend.13.11.0370 https://doi.org/10.1210/mend.13.11.0370
64. PakarainenTZhangFPNurmiLPoutanenMHuhtaniemiI. Knockout of luteinizing hormone receptor abolishes the effects of follicle-stimulating hormone on preovulatory matura tion and ovulation of mouse graafian follicles. Mol Endocrinol. 2005; 19(10): 2591-2602. doi: 10.1210/me.2005-007510.1210/me.2005-0075 https://doi.org/10.1210/me.2005-0075
65. De BaereEBeysenDOleyC. FOXL2 and BPES: Mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet. 2003; 72(2): 478-487. doi: 10.1086/34611810.1086/346118 https://doi.org/10.1086/346118
66. MuWWenHLiJHeF. Cloning and expression analysis of a HSP70 gene from Korean rockfish (Sebastes schlegeli). Fish Shellfish Immunol. 2013; 35(4): 1111-1121. doi: 10.1016/j. fsi.2013.07.02210.1016/j.fsi.2013.07.022 https://doi.org/10.1016/j.fsi.2013.07.022
67. Kohno S, Katsu Y, Urushitani H, Ohta Y, Iguchi T, Guillette LJ Jr. Potential contributions of heat shock proteins to temperature-dependent sex determination in the American alligator. Sex Dev. 2010; 4(1-2): 73-87. doi: 10.1159/000260374 https://doi.org/10.1159/000260374
68. KimHChunSGuBSKuSYKimSHKimJG. Relationship between inhibin-α gene polymorphisms and premature ovarian failure in Korean women. Menopause. 2011; 18(11): 1232-1236. doi: 10.1097/gme.0b013e31821d6f7e10.1097/gme.0b013e31821d6f7e https://doi.org/10.1097/gme.0b013e31821d6f7e
69. ChandALHarrisonCAShellingAN. Inhibin and premature ovarian failure. Hum Reprod Update. 2010; 16(1): 39-50. doi: 10.1093/humupd/dmp03110.1093/humupd/dmp031 https://doi.org/10.1093/humupd/dmp031
70. RajkovicAPangasSABallowDSuzumoriNMatzukMM. NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. Science. 2004; 305(5687): 1157- 1159. doi: 10.1126/science.109975510.1126/science.1099755 https://doi.org/10.1126/science.1099755
71. QinYShiYZhaoYCarsonSASimpsonJLChenZJ. Mutation analysis of NOBOX homeodomain in Chinese women with premature ovarian failure. Fertil Steril. 2009; 91(4 Suppl): 1507-1509. doi: 10.1016/j.fertnstert.2008.08.02010.1016/j.fertnstert.2008.08.020 https://doi.org/10.1016/j.fertnstert.2008.08.020
72. WangJWangBSongJ. New candidate gene POU5F1 associated with premature ovarian failure in Chinese patients. Reprod Biomed Online. 2011; 22(3): 312-316. doi: 10.1016/j. rbmo.2010.11.00810.1016/j.rbmo.2010.11.008 https://doi.org/10.1016/j.rbmo.2010.11.008
73. AchermannJCOzisikGMeeksJJJamesonJL. Perspective: Genetic causes of human reproductive diseases. J Clin Endocrinol Metab. 2002, 87(6): 2447-2454. doi: 10.1210/jc.87.6.244710.1210/jc.87.6.2447 https://doi.org/10.1210/jc.87.6.2447
74. La Marca A, Brozzetti A, Sighinolfi G, Marzotti S, V olpe A, Falorni A. Primary ovarian insufficiency: Autoimmune causes. Curr Opin Obstet Gynecol. 2010; 22(4): 277-282. doi: 10.1097/ GCO.0b013e32833b6c70
75. Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Car valho JF, Bonfá E. Autoimmune primary ovarian insufficiency. Autoimmun Rev. 2014; 13(4-5): 427-430. doi: 10.1016/j.autrev.2014.01.003 https://doi.org/10.1016/j.autrev.2014.01.003
76. TuohyVKAltuntasCZ. Autoimmunity and premature ovarian failure. Curr Opin Obstet Gynecol. 2007; 19(4): 366-369. doi: 10.1097/GCO.0b013e328220e90c10.1097/gco.0b013e328220e90c https://doi.org/10.1097/gco.0b013e328220e90c
77. MeskhiASeifMW. Premature ovarian failure. Curr Opin Obstet Gynecol. 2006; 18(4): 418-426
78. RebarRW. Premature ovarian failure. Obstet Gynecol. 2009; 113(6): 1355-1363. doi: 10.1097/AOG.0b013e3181a6684310.1097/aog.0b013e3181a66843 https://doi.org/10.1097/aog.0b013e3181a66843
79. Dragojević-DikićSMarisavljevićDMitrovićADikićSJovanovićTJanković-RaznatovićS. An immunological insight into premature ovarian failure (POF). Autoimmun Rev. 2010; 9(11): 771-774. doi: 10.1016/j.autrev.2010.06.00810.1016/j.autrev.2010.06.008 https://doi.org/10.1016/j.autrev.2010.06.008
80. PanayNKaluE. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol. 2009; 23(1): 129-140. doi: 10.1016/j.bpobgyn.2008.10.00810.1016/j.bpobgyn.2008.10.008 https://doi.org/10.1016/j.bpobgyn.2008.10.008
81. AsbaghFAEbrahimiM. A case report of spontaneous pregnancy during hormonal replacement therapy for premature ovarian failure. Iran J Reprod Med. 2011; 9(1): 47-49. Web site. http://pubmedcentralcanada.ca/pmcc/articles/PMC4212146/. Accessed January 27, 2017
82. EbrahimiMAsbaghFA. The role of autoimmunity in premature ovarian failure. Iran J Reprod Med. 2015; 13(8): 461- 472
83. KholeV. Does ovarian autoimmunity play a role in the pathophysiology of premature ovarian insufficiency? J Midlife Health. 2010; 1(1): 9-13. doi: 10.4103/0976-7800.6698610.4103/0976-7800.66986 https://doi.org/10.4103/0976-7800.66986
84. ForgesTMonnier-BarbarinoPFaureGCBénéMC. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update. 2004; 10(2): 163-175. doi: 10.1093/humupd/ dmh01410.1093/humupd/dmh014 https://doi.org/10.1093/humupd/dmh014
85. PiresESMeherjiPKVaidyaRRParikhFRGhosalkarMNKholeVV. Specific and sensitive immunoassays detect multiple anti-ovarian antibodies in women with infertility. J Histochem Cytochem. 2007; 55(12): 1181-1190. Web site. http:// journals.sagepub.com/doi/abs/10.1369/jhc.7A7259.2007. Accessed January 27, 201710.1369/jhc.7a7259.2007.accessed https://doi.org/10.1369/jhc.7a7259.2007.accessed
86. PoppeKGlinoerDTournayeH. Thyroid autoimmu nity and female infertility. Verh K Acad Geneeskd Belg. 2006; 68(5-6): 357-377. Web site. http://europepmc.org/abstract/ med/17313094. Accessed January 27, 2017
87. ShamilovaNNMarchenkoLADolgushinaNVZaletaevDVSukhikhGT. The role of genetic and autoimmune factors in premature ovarian failure. J Assist Reprod Genet. 2013; 30(5): 617-622. doi: 10.1007/s10815-013-9974-410.1007/s10815-013-9974-4 https://doi.org/10.1007/s10815-013-9974-4
88. CarsoteMValeaA. Premature ovarian failure of autoim mune causes. J Gynecol Neonatal Biol. 2015; 1(1): 1-2. Web site. http://www.ommegaonline.org/article-details/Prematureovarian-failure-of-autoimmune-causes/364. Accessed January 27, 2017
89. CarpHJSelmiCShoenfeldY. The autoimmune bases of infertility and pregnancy loss. J Autoimmun. 2012; 38(2-3): J266-J274. doi: 10.1016/j.jaut.2011.11.01610.1016/j.jaut.2011.11.016 https://doi.org/10.1016/j.jaut.2011.11.016
90. CerveraRBalaschJ. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update. 2008; 14(4): 359-366. doi: 10.1093/humupd/dmn01310.1093/humupd/dmn013 https://doi.org/10.1093/humupd/dmn013
91. Monnier-BarbarinoPForgesTFaureGCBénéMC. Gonadal antibodies interfering with female reproduction. Best Pract Res Clin Endocrinol Metab. 2005; 19(1): 135-148. doi: 10.1016/j.beem.2004.11.01110.1016/j.beem.2004.11.011 https://doi.org/10.1016/j.beem.2004.11.011
92. LuborskyJPongR. Pregnancy outcome and ovarian anti bodies in infertility patients undergoing controlled ovarian hyperstimulation. Am J Reprod Immunol. 2000; 44(5): 261-265. doi: 10.1111/j.8755-8920.2000.440502.x10.1111/j.8755-8920.2000.440502.x https://doi.org/10.1111/j.8755-8920.2000.440502.x
93. ReatoGMorlinLChenS. Premature ovarian failure in patients with autoimmune Addison’s disease: Clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab. 2011; 96(8): E1255-E1261. doi: 10.1210/jc.2011-041410.1210/jc.2011-0414 https://doi.org/10.1210/jc.2011-0414
94. Dal Pra C, Chen S, Furmaniak J, et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian fail ure with and without Addison’s disease. Eur J Endocrinol. 2003; 148(5): 565-570. doi: 10.1530/eje.0.1480565 https://doi.org/10.1530/eje.0.1480565
95. Chiauzzi V A, Bussmann L, Calvo JC, Sundblad V, Charreau EH. Circulating immunoglobulins that inhibit the binding of follicle-stimulating hormone to its receptor: A putative diagnostic role in resistant ovary syndrome? Clin Endocrinol (Oxf). 2004; 61(1): 46-54. doi: 10.1111/j.1365-2265.2004.02054.x https://doi.org/10.1111/j.1365-2265.2004.02054.x
96. Ryan MM, Jones HR Jr. Myasthenia gravis and premature ovarian failure. Muscle Nerve. 2004; 30(2): 231-233. doi: 10.1002/mus.20067 https://doi.org/10.1002/mus.20067
97. GobertBJolivet-ReynaudCDalbonP. An immuno reactive peptide of the FSH involved in autoimmune infertility. Biochem Biophys Res Commun. 2001; 289(4): 819-824. doi: 10.1006/bbrc.2001.605910.1006/bbrc.2001.6059 https://doi.org/10.1006/bbrc.2001.6059
98. KoyamaKHasegawaA. Premature ovarian failure syn-Page 54 drome may be induced by autoimmune reactions to zona pellucid proteins. J Reprod Endocrinol. 2006; 3: 94-97. Web site. http://www.kup.at/journals/abbildungen/gross/6633.html. Accessed January 27, 2017
99. LuborskyJLVisintinIBoyersSAsariTCaldwellBDeCherneyA. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab. 1990; 70(1): 69-75. doi: 10.1210/jcem- 70-1-6910.1210/jcem-70-1-69 https://doi.org/10.1210/jcem-70-1-69
100. PasotoSGVianaVSMendoncaBBYoshinariNHBonfaE. Anti-corpus luteum antibody: A novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol. 1999; 26(5): 1087-1093. Web site. http://europepmc.org/ abstract/med/10332973. Accessed January 27, 2017
101. FalorniALauretiSCandeloroP. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril. 2002; 78(2): 270-279. doi: 10.1016/S0015-0282(02)03205-310.1016/s0015-0282(02)03205-3 https://doi.org/10.1016/s0015-0282(02)03205-3
102. WeltCK. Autoimmune oophoritis in the adolescent. Ann N Y Acad Sci. 2008; 1135: 118-122. doi: 10.1196/annals.1429.00610.1196/annals.1429.006 https://doi.org/10.1196/annals.1429.006
103. WémeauJLProust-LemoineERyndakAVanhoveL. Thyroid autoimmunity and polyglandular endocrine syndromes. Hormones (Athens). 2013; 12(1): 39-45. Web site. http://www. hormones.gr/pdf/HORMONES2013,39-45.pdf. Accessed January 27, 2017
104. AbalovichMMitelbergLAllamiC. Subclini cal hypothyroidism and thyroid autoimmunity in women with infertility. Gynecol Endocrinol. 2007; 23(5): 279-283. doi: 10.1080/0951359070125954210.1080/09513590701259542 https://doi.org/10.1080/09513590701259542
105. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002; 23(3): 327- 364. doi: 10.1210/edrv.23.3.0466 https://doi.org/10.1210/edrv.23.3.0466
106. EuthymiopoulouKAletrasAJRavazoulaP. Antiovarian antibodies in primary Sjogren’s syndrome. Rheumatol Int. 2007; 27(12): 1149-1155. doi: 10.1007/s00296-007-0364-z10.1007/s00296-007-0364-z https://doi.org/10.1007/s00296-007-0364-z
107. SklarC. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr. 2005; 34: 25-27. Web site. http://citeseerx.ist.psu. edu/viewdoc/download?doi=10.1.1.589.3491&rep=rep1&type =pdf. Accessed January 27, 2017
108. RebarRW. Premature ovarian “failure” in the adolescent. Ann N Y Acad Sci. 2008; 1135: 138-145. doi: 10.1196/annals.1429.00010.1196/annals.1429.000 https://doi.org/10.1196/annals.1429.000
109. WallaceWHBThomsonABKelseyTW. The radiosensitivity of the human oocyte. Hum Reprod. 2003; 18(1): 117-121. doi: 10.1093/humrep/deg01610.1093/humrep/deg016 https://doi.org/10.1093/humrep/deg016
110. AshP. The influence of radiation on fertility in man. Br J Radiol. 1980; 53(628): 271-278. doi: 10.1259/0007-1285-53- 628-27110.1259/0007-1285-53-628-271 https://doi.org/10.1259/0007-1285-53-628-271
111. GraciaCRSammelMDFreemanE. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012; 97(1): 134-140. doi: 10.1016/j.fertnstert.2011.10.04010.1016/j.fertnstert.2011.10.040 https://doi.org/10.1016/j.fertnstert.2011.10.040
112. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod. 2009; 24(4): 982- 990. doi: 10.1093/humrep/den487 https://doi.org/10.1093/humrep/den487
113. OktemOOktayK. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007; 110(10): 2222-2229. doi: 10.1002/cncr.2307110.1002/cncr.23071 https://doi.org/10.1002/cncr.23071
114. WallaceWH. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer. 2011; 117(10 Suppl): 2301-2310. doi: 10.1002/cncr.2604510.1002/cncr.26045 https://doi.org/10.1002/cncr.26045
115. FentonAPanayN. Does routine gynecological surgery contribute to an early menopause? Climacteric. 2012; 15(1): 1-2. doi: 10.3109/13697137.2012.64762310.3109/13697137.2012.647623 https://doi.org/10.3109/13697137.2012.647623
116. KovacsPStangelJJSantoroNFLiemanH. Successful pregnancy after transient ovarian failure following treatment of symptomatic leiomyomata. Fertil Steril. 2002; 77(6): 1292- 1295. doi: 10.1016/S0015-0282(02)03091-110.1016/s0015-0282(02)03091-1 https://doi.org/10.1016/s0015-0282(02)03091-1
117. ConwayGS. Premature ovarian failure. Br Med Bull. 2000; 56(3): 643-649. doi: 10.1258/000714200190344510.1258/0007142001903445 https://doi.org/10.1258/0007142001903445
118. LongwayMMatthewsCA. Resumption of ovarian function 20 years after chemotherapy-induced ovarian failure: A case report. Fertil Steril. 2009; 92(1): e17-e18. doi: 10.1016/j.fertnstert.2009.02.08210.1016/j.fertnstert.2009.02.082 https://doi.org/10.1016/j.fertnstert.2009.02.082
119. WikströmAMHoviLDunkelLSaarinen-PihkalaUM. Restoration of ovarian function after chemotherapy for osteosarcoma. Arch Dis Child. 2003; 88(5): 428-431. doi: 10.1136/ adc.88.5.428
120. WangHChenHQinY. Risks associated with premature ovarian failure in Han Chinese women. Reprod Biomed Online. 2015; 30(4): 401-407. doi: 10.1016/j.rbmo.2014.12.01310.1016/j.rbmo.2014.12.013 https://doi.org/10.1016/j.rbmo.2014.12.013
121. OhlJPartisaniMDemangeatCBinder-FoucardFNisandILangJM. [Alterations of ovarian reserve tests in Human Immunodeficiency Virus (HIV)-infected women]. Gynecol Obstet Fertil. 2010; 38(5): 313-317. doi: 10.1016/j.gyobfe.2009.07.019 Page 5510.1016/j.gyobfe.2009.07.019 https://doi.org/10.1016/j.gyobfe.2009.07.019
122. ChangSHKimCSLeeKS. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas. 2007; 58(1): 19-30. doi: 10.1016/j.maturitas.2007.04.00110.1016/j.maturitas.2007.04.001 https://doi.org/10.1016/j.maturitas.2007.04.001
123. Di ProsperoFLuziSIacopiniZ. Cigarette smoking damages women’s, reproductive life. Reprod Biomed Online. 2004; 8(2): 246-247. doi: 10.1016/S1472-6483(10)60525-110.1016/s1472-6483(10)60525-1 https://doi.org/10.1016/s1472-6483(10)60525-1
124. PanayNMaclaranKNicopollousJHornerEDomoneyC. Findings from the West London Menopause and PMS Centre POF Database. In: Proceedings of the 32 nd British Belfast, Northern Ireland, UK: International congress of obstetrics and gynaecology; 2010: 20-23
125. European Society for Human Reproduction and Embryol ogy (ESHRE) Guideline Group on POI, Webber L, Davies M, et al. ESHRE Guideline: Management of women with premature ovarian insufficiency. Hum Reprod. 2016; 31(5): 926-937. doi: 10.1093/humrep/dew027 https://doi.org/10.1093/humrep/dew027
126. DavisSRJaneF. Sex and perimenopause. Aust Fam Physician. 2011; 40(5): 274-278. Web site. http://search.proquest. com/openview/ca481b530410c94899ccd04ec868a360/1?pqorigsite=gscholar&cbl=33668. Accessed January 27, 2017
127. SmithJAVitaleSReedGF. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol. 2004; 122(2): 151-156. doi: 10.1001/archopht.122.2.15110.1001/archopht.122.2.151 https://doi.org/10.1001/archopht.122.2.151
128. KnauffEAEijkemansMJLambalkCB. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009; 94(3): 786-792. doi: 10.1210/jc.2008-181810.1210/jc.2008-1818 https://doi.org/10.1210/jc.2008-1818
129. KumarNSinghAK. Role of Antimüllerian hormone in gynecology: A review of literature. Int J Infertil Fetal Med. 2015; 6(2): 51-61
130. CateRLMattalianoRJHessionC. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986; 45(5): 685-698. doi: 10.1016/0092-8674(86)90783-X10.1016/0092-8674(86)90783-x https://doi.org/10.1016/0092-8674(86)90783-x
131. DurlingerALGruijtersMJKramerP. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002; 143(3): 1076-1084. doi: 10.1210/endo.143.3.869110.1210/endo.143.3.8691 https://doi.org/10.1210/endo.143.3.8691
132. DurlingerALKramerPKarelsB. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999; 140(12): 5789-5796. doi: 10.1210/ endo.140.12.7204
133. NardoLGChristodoulouDGouldDRobertsSAFitzgeraldCTLaingI. Anti-Müllerian hormone levels and antral follicle count in women enrolled in in-vitro fertilization cycles: Relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol. 2007; 23(8): 486-493. doi: 10.1080/09513590701532815 van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010; 25(1): 221-227. doi: 10.1093/humrep/dep36610.1080/09513590701532815 https://doi.org/10.1080/09513590701532815
134. LavenJSMuldersAGVisserJAThemmenAPDe JongFHFauserBC. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89(1): 318-323. doi: 10.1210/ jc.2003-030932
135. VisserJASchipperILavenJSThemmenAP. Anti-Müllerian hormone: An ovarian reserve marker in primary ovar ian insufficiency. Nat Rev Endocrinol. 2012; 8(6): 331-41. doi: 10.1038/nrendo.2011.22410.1038/nrendo.2011.224 https://doi.org/10.1038/nrendo.2011.224
136. NelsonSM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013; 99(4): 963-969. doi: 10.1016/j.fertnstert.2012.11.05110.1016/j.fertnstert.2012.11.051 https://doi.org/10.1016/j.fertnstert.2012.11.051
137. Committee opinion no. 605: Primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014; 124(1): 193-197
138. HalderAFauzdarAGhoshMKumarA. Serum inhibin B: A direct and precise marker of ovarian function. J Clin Diagn Res. 2007: 1: 131-137. Web site. http://www.jcdr.net/back_issues.asp?issn=0973-709x&year=2007&month=June&volume=1&issue=3&page=131-137&id=69. Accessed January 27, 2017
139. De CaroJJDominguezCShermanSL. Reproductive health of adolescent girls who carry the FMR1 premutation: Expected phenotype based on current knowledge of fragile X-associated primary ovarian insufficiency. Ann N Y Acad Sci. 2008; 1135: 99-111. doi: 10.1196/annals.1429.02910.1196/annals.1429.029 https://doi.org/10.1196/annals.1429.029
140. Ben-NagiJPanayN. Premature ovarian insufficiency: How to improve reproductive outcome? Climacteric. 2014; 17(3): 242-246. doi: 10.3109/13697137.2013.86011510.3109/13697137.2013.860115 https://doi.org/10.3109/13697137.2013.860115
141. Schmidt KT, Nyboe Andersen A, Greve T, Ernst E, Loft A, Yding Andersen C. Fertility in cancer patients after cryopreser vation of one ovary. Reprod Biomed Online. 2013; 26(3): 272- 279. doi: 10.1016/j.rbmo.2012.12.001 https://doi.org/10.1016/j.rbmo.2012.12.001
142. DonnezJDolmansMMPellicerA. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: A review of 60 cases of reimplanta tion. Fertil Steril. 2013; 99(6): 1503-1513. doi: 10.1016/j.fertnstert.2013.03.030 Page 5610.1016/j.fertnstert.2013.03.030 https://doi.org/10.1016/j.fertnstert.2013.03.030
143. LutjenPTrounsonALeetonJFindlayJWoodCRenouP. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature. 1984; 307(5947): 174-175. doi: 10.1038/307174a010.1038/307174a0 https://doi.org/10.1038/307174a0
144. SirolaJKrögerHHonkanenR. Smoking may impair the bone protective effects of nutritional calcium: A populationbased approach. J Bone Miner Res. 2003; 18(6): 1036-1042. doi: 10.1359/jbmr.2003.18.6.103610.1359/jbmr.2003.18.6.1036 https://doi.org/10.1359/jbmr.2003.18.6.1036
145. BanksEReevesGKBeralVBalkwillALiuBRoddamA. Million Women Study Collaborators. Hip fracture incidence in relation to age, menopausal status, and age at menopause: Prospective analysis. PLoS Med. 2009; 6(11): e1000181. doi: 10.1371/journal.pmed.100018110.1371/journal.pmed.1000181 https://doi.org/10.1371/journal.pmed.1000181
146. ManolagasSCO’BrienCAAlmeidaM. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013; 9(12): 699-712. doi: 10.1038/nrendo.2013.17910.1038/nrendo.2013.179 https://doi.org/10.1038/nrendo.2013.179
147. BachelotARouxelAMassinN. POF-GIS Study Group. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol. 2009; 161(1): 179-1487. doi: 10.1530/EJE-09-023110.1530/eje-09-0231 https://doi.org/10.1530/eje-09-0231
148. FreriksKTimmermansJBeerendonkCC. Standardized multidisciplinary evaluation yields significant previously undiagnosed morbidity in adult women with turner syndrome. J Clin Endocrinol Metab. 2011; 96(9): E1517-E1526. doi: 10.1210/jc.2011-034610.1210/jc.2011-0346 https://doi.org/10.1210/jc.2011-0346
149. PopatVBCalisKAVanderhoofVH. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009; 94(7): 2277-2283. doi: 10.1210/jc.2008-1878 van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996; 347(9003): 714-718. doi: 10.1016/S0140-6736(96)90075-610.1210/jc.2008-1878 https://doi.org/10.1210/jc.2008-1878
150. AtsmaFBartelinkMLGrobbeeDEvan der SchouwYT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis. Menopause. 2006; 13(2): 265-279. doi: 10.1097/01.gme.0000218683.97338. ea10.1097/01.gme.0000218683.97338.ea https://doi.org/10.1097/01.gme.0000218683.97338.ea